Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis

BackgroundThe objective of this study is to assess the relative efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab, evolocumab, and inclisiran, in conjunction with potent statins like atorvastatin and rosuvastatin, in patients presenting with hyperlipide...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuhua Jiang, Yingying Wang, Sijia Ma, Linlin Qian, Yeteng Jing, Xi Chen, Jinsheng Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
hyperlipidemia
LDL-C
PCSK9 inhibitors
potent statins
network meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1415668/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items